Leukotrienes modulate secretion of progesterone and prostaglandins during the estrous cycle and early pregnancy in cattle: an in vivo study.
Recently, we showed that leukotrienes (LTs) regulate ovarian cell function in vitro. The aim of this study was to examine the role of LTs in corpus luteum (CL) function during both the estrous cycle and early pregnancy in vivo. mRNA expression of LT receptors (BLT for LTB(4) and CYSLT for LTC(4)), and 5-lipoxygenase (5-LO) in CL tissue and their localization in the ovary were studied during the estrous cycle and early pregnancy. Moreover, concentrations of LTs (LTB(4) and C(4)) in the CL tissue and blood were measured. 5-LO and BLT mRNA expression increased on days 16-18 of the cycle, whereas CYSLT mRNA expression increased on days 16-18 of the pregnancy. The level of LTB(4) was evaluated during pregnancy compared with the level of LTC(4), which increased during CL regression. LT antagonists influenced the duration of the estrous cycle: the LTC(4) antagonist (azelastine) prolonged the luteal phase, whereas the LTB(4) antagonist (dapsone) caused earlier luteolysis in vivo. Dapsone decreased progesterone (P(4)) secretion and azelastine increased P(4) secretion during the estrous cycle. In summary, LT action in the bovine reproductive tract is dependent on LT type: LTB(4) is luteotropic during the estrous cycle and supports early pregnancy, whereas LTC(4) is luteolytic, regarded as undesirable in early pregnancy. LTs are produced/secreted in the CL tissue, influence prostaglandin function, and serve as important factors during the estrous cycle and early pregnancy in cattle.
Korzekwa
Anna J
AJ
Department of Reproductive Immunology and Pathology, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, 10-747 Olsztyn, Poland. a.korzekwa@pan.olsztyn.pl
Bah
Mamadou M
MM
Kurzynowski
Andrzej
A
Lukasik
Karolina
K
Groblewska
Agnieszka
A
Skarzynski
Dariusz J
DJ
D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000097:blood / Q000502:physiology*; D002417:Cattle / Q000502:physiology*; D003338:Corpus Luteum / Q000502:physiology*; D003622:Dapsone / Q000494:pharmacology; D030762:Estrous Cycle / Q000502:physiology*; D005260:Female; D007150:Immunohistochemistry / Q000662:veterinary; D007975:Leukotriene B4 / Q000037:antagonists & inhibitors / Q000097:blood / Q000235:genetics / Q000502:physiology*; D017997:Leukotriene C4 / Q000037:antagonists & inhibitors / Q000097:blood / Q000235:genetics / Q000502:physiology*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D010793:Phthalazines / Q000494:pharmacology; D011247:Pregnancy; D012333:RNA, Messenger / Q000737:chemistry / Q000235:genetics; D018077:Receptors, Leukotriene / Q000502:physiology; D018102:Receptors, Leukotriene B4 / Q000502:physiology; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000662:veterinary
D016859:Lipoxygenase Inhibitors; D010793:Phthalazines; D012333:RNA, Messenger; D018077:Receptors, Leukotriene; D018102:Receptors, Leukotriene B4; C083173:leukotriene C4 receptor; D007975:Leukotriene B4; D017997:Leukotriene C4; D003622:Dapsone; D001094:Arachidonate 5-Lipoxygenase; C020976:azelastine